In The News Posted January 31, 2019 Share Posted January 31, 2019 MINNEAPOLIS, Jan. 31, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.